AI news
Coherence Neuro says investors backed its AI-enabled cancer-device work with $45 million
Coherence Neuro says Founders Fund and the OpenAI Startup Fund backed it with $45 million to develop implantable devices and algorithms that could monitor tumor changes. Its original research account describes preclinical mouse-model results and early human device testing; adaptive cancer treatment and regulatory designation remain goals, not established clinical benefits. The company does not state a valuation.
Primary source · Coherence Neuro · October 21, 2026
Opens Coherence Neuro in a new tab. Read it there before you rely on the summary above.
Read the original
Free, email only
Unlock the full brief free.
- What to check before you trust this story, written down
- Each verified source, with why it matters and who published it
- A note whenever a source has been withdrawn
- Thirty days of stories to browse, not seven
Continuing subscribes the email on that account to Work Worth Doing, my newsletter, the same as the form below, and unlocks every free tool in this browser. We only receive your email address. Unsubscribe in one click.